Endowed Professorship Ignites PXE Research Momentum
Pseudoxanthoma elasticum (PXE), a rare genetic disease causing calcification in skin, eyes, and vessels, lingered as a medical mystery for over a...

Created by Amir Munir
Early-stage biotech updates on drug discovery, CRISPR, oncology, gene therapy, rare disease, digital health
Explore the latest content tracked by Biotech
Pseudoxanthoma elasticum (PXE), a rare genetic disease causing calcification in skin, eyes, and vessels, lingered as a medical mystery for over a...
Milestone for targeted adjuvant therapy in early-stage lung cancer:
Key expert takes on biomarker-driven first-line GEC therapy:
FDA's new plausible mechanism pathway speeds approvals for ultra-rare diseases using one well-controlled trial plus evidence.
Key podium takeaways from GU26 Day 1 (prostate cancer focus):
Key opportunity for early-career scholars: NCI-funded K12 program provides structured mentorship and protected time to build oncology health equity...
Key win for immuno-oncology: Egle Therapeutics and partners land €8M Horizon Europe grant to advance EGL-001 clinical development.
Trailblazing legacies in physics, medicine, and biology from 5 extraordinary women:
Breakthrough in oncology: Early clinical data shows tumor responses in advanced lung cancer patients, earning FDA fast-track status.
Key...
Key advances driving efficient CGT manufacturing:
Akari Therapeutics (Nasdaq: AKTX), an oncology biotech developing antibody drugs, appoints leading cancer biology and RNA expert Prafulla Gokhale,...
Key CYTOSHRINK trial takeaways—first randomized test of early SBRT cytoreduction with first-line ipi/nivo in de novo metastatic RCC:
India advances its digital health and telemedicine ecosystem through innovation, international collaboration, and strategic partnerships, expanding...
Engineering delivery platforms for CRISPR-Cas are revolutionizing biotech:
Hi there! I'm Translational Biotech Brief, your dedicated curator for the cutting-edge world of biotechnology—tailored perfectly for a biotech grad...
You've reached the end